Works Cited

1. Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol. 2008;16(5):405-416.

2. Bruehl S, Apkarian AV, Ballantyne JC, et al. Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges. J Pain. 2013;14(2):103-113.

3. Breuer B, Pappagallo M, Tai JY, Portenoy RK. U.S. board-certified pain physician practices: uniformity and census data of their locations. J Pain. 2007;8(3):244-250.

4. Schatman ME. The role of the health insurance industry in perpetuating suboptimal pain management. Pain Med. 2011;12(3): 415-426.

5. Schatman ME, Lebovits AH. On the transformation of the "profession" of pain medicine to the "business" of pain medicine: an introduction to a special series. Pain Med. 2011;12(3):403-405.

6. Webster LR, Cochella S, Dasgupta N, et al. An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Medicine. 2011;12(Suppl 2):S26-S35.

7. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press; 2011.

8. Finch JW. Challenges of chronic pain management: public health consequences and considered responses. N C Med J. 2013;74(3):243-248.

9. American Academy of Family Physicians. Chronic Opioid Therapy Webcast. Available at http://www.aafp.org/cme/cme-topic/all/chronic-opioid-therapy.html. Last accessed July 5, 2017.

10. Federation of State Medical Boards. Model Policy for the Use of Opioid Analgesics in the Treatment of Chronic Pain. Washington, DC: Federation of State Medical Boards; 2013.

11. PRNewswire. U.S. Public and Doctors' Misperceptions Revealed in National Survey Demonstrate Urgent Need for Increased Opioid Dependence Awareness. Available at http://www.prnewswire.com/news-releases/us-public-and-doctors-misperceptions-revealed-in-national-survey-demonstrate-urgent-need-for-increased-opioid-dependence-awareness-210981471.html. Last accessed July 5, 2017.

12. Leavitt SB. Survey Shows Opioid "Addiction" Misunderstood. Available at https://neuropathyandhiv.blogspot.com/2013/07/understanding-opioid-addiction.html. Last accessed July 5, 2017.

13. Bhamb B, Brown D, Hariharan J, et al. Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin. 2006;22(9):1859-1865.

14. Mezei L, Murinson BB; Johns Hopkins Pain Curriculum Development Team. Pain education in North American medical schools.J Pain. 2011;12(12):1199-1208.

15. Oliver J, Coggins C, Compton P, et al. American Society for Pain Management Nursing position statement: pain management in patients with substance use disorders. Pain Manage Nurs. 2012;13(3):169-183.

16. American Psychiatric Association. DSM-5 Fact Sheets: Changes in the New Edition. Available at https://www.psychiatry.org/psychiatrists/practice/dsm/educational-resources/dsm-5-fact-sheets. Last accessed July 5, 2017.

17. American Society of Addiction Medicine. Definition of Addiction. Available at https://www.asam.org/quality-practice/definition-of-addiction. Last accessed July 5, 2017.

18. Wallace LS, Keenum AJ, AbdurRaqeeb O, et al. Terminology matters: patient understanding of "opioids" and "narcotics." Pain Pract. 2013;13(2):104-108.

19. Prince V. Pain management in patients with substance-use disorders. In: Chronic Illnesses I, II, and IIIPSAP-VII, Book 5. Lenexa, KS: American College of Clinical Pharmacology; 2011.

20. Utah Department of Health. Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain. Salt Lake City, UT: Utah Department of Health; 2009.

21. American Academy of Family Physicians. Under-Treatment of Pain: Resources for Pain Management. Available at http://www.aafp.org/dam/AAFP/documents/cme/chronic_pain/CLS_PainResources.pdf. Last accessed July 5, 2017.

22. Chou R, Fanciullo GJ, Fine PG, et al. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors—a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10(2):131-146.

23. Passik SD, Kirsh SL, Whitcomb L, Dickerson PK, Theobald DE. Pain clinicians' rankings of aberrant drug-taking behaviors. J Pain Palliative Care Pharmacother. 2002;16(4):39-49.

24. Baxter J. Minimizing the Misuse of Prescription Opioids in Patients with Chronic Nonmalignant Pain. Available at http://www.drugabuse.gov/nidamed/centers-excellence/resources/minimizing-misuse-prescription-opioids-in-patients-chronic-nonmalignant-pain. Last accessed July 5, 2017.

25. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc. 2009;84(7):593-601.

26. Holliday S, Hayes C, Dunlop A. Opioid use in chronic noncancer pain. Part 2: prescribing issues and alternatives. Aust Fam Physician. 2013;42(3):104-111.

27. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005;6(6):432-442.

28. Hill CS. Government regulatory influences on opioid prescribing and their impact on the treatment of pain of non-malignant origin. J Pain Symptom Manage. 1996;11(5):287-298.

29. Joranson DE, Cleeland CS, Weissman DE, et al. Opioids for chronic cancer and noncancer pain: survey of state medical board members. Fed Bull J Med Licensure Discipline. 1992;79;15-49.

30. Catan T, Perez E. A Pain-Drug Champion Has Second Thoughts. Available at http://online.wsj.com/news/articles/SB10001424127887324478304578173342657044604. Last accessed July 5, 2017.

31. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain. 1986;25:171-186.

32. Portenoy RK. Chronic opioid therapy for nonmalignant pain: from models to practice. APS J. 1992;1:285-288.

33. Portenoy RK. Chronic opioid therapy in nonmalignant pain. J Pain Symptom Manage. 1990;5:46-62.

34. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage. 1996;11: 203-217.

35. Portenoy RK. Opioid therapy for chronic nonmalignant pain: clinician's perspective. J Law Med Ethics. 1996;24:296-309.

36. Porter J, Jick H. Addiction rare in patients treated with narcotics. N Engl J Med. 1980;302:123.

37. Perry S, Heidrich G. Management of pain during debridement: a survey of U.S. burn units. Pain. 1982;13:267-280.

38. Medina JL, Diamond S. Drug dependency in patients with chronic headache. Headache. 1977;17:12-14.

39. Melzack R. The tragedy of needless pain. Sci Am. 1990;262:27-33.

40. American Academy of Pain Medicine, American Pain Society. The use of opioids for the treatment of chronic pain: a consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain. 1997;13(1):6-8.

41. Gussow L. Toxicology rounds: the dark truth behind pain as the fifth vital sign. EMN. 2013;35(3):4-5.

42. Compton WM. Prescription Drug Abuse: It's Not What the Doctor Ordered. Available at http://www.apa.org/about/gr/science/spin/2013/05/prescription-drug-abuse.pdf. Last accessed July 5, 2017.

43. U.S. General Accounting Office. Report to Congressional Requesters: Prescription Drugs: OxyContin Abuse and Diversion and Efforts to Address the Problem. Available at http://www.gao.gov/new.items/d04110.pdf. Last accessed July 5, 2017.

44. Owen GT, Burton AW, Schade CM, Passik S. Urine drug testing: current recommendations and best practices. Pain Physician. 2012;15(3 Suppl):ES119-ES133.

45. Meier B. The Delicate Balance of Pain and Addiction. Available at http://www.nytimes.com/2003/11/25/science/the-delicate-balance-of-pain-and-addiction.html. Last accessed July 5, 2017.

46. Van Rooyan KW, Gelfand SG, Van Zee A, et al. A message from advocates for prescription opioid drug reform. Pain Physician. 2008;11:S63-S88.

47. Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician. 2008;11(2 Suppl):S63-S88.

48. Manchikanti L, Abdi S, Atluri S, et al.; American Society of Interventional Pain Physicians. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic noncancer pain: Part 2—guidance. Pain Physician. 2013;16:S49-S283.

49. Center for Substance Abuse Treatment. OxyContin: Prescription drug abuse—2008 revision. Available at http://store.samhsa.gov/shin/content/SMA08-4138/SMA08-4138.pdf. Last accessed July 5, 2017.

50. Van Zee A. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Am J Public Health. 2009;99(2):221-227.

51. Tough P. The Alchemy of OxyContin. Available at http://www.nytimes.com/2001/07/29/magazine/the-alchemy-of-oxycontin.html. Last accessed July 5, 2017.

52. Katz DA, Hays LR. Adolescent OxyContin abuse. J Am Acad Child Adolesc Psychiatry. 2004;4392):231-234.

53. Jayawant SS, Balkrishnan R. The controversy surrounding OxyContin abuse: issues and solutions. Ther Clin Risk Manag. 2005;1(2):77-82.

54. Brushwood DB. Why is Our Government Pursuing a War on Doctors? Available at http://www.dailystrength.org/c/Chronic_Pain/forum/10867676-why-our-government-pursuing. Last accessed July 5, 2017.

55. Whelan E, Asbridge M, Haydt S. Representations of OxyContin in North American newspapers and medical journals. Pain Res Manage. 2011;16(4):252-258.

56. Giordano J, Schatman ME, Höver G. Ethical insights to rapprochement in pain care: bringing stakeholders together in the best interest(s) of the patient. Pain Physician. 2009;12(4):E265-E275.

57. Department of Health and Human Services. The Opioid Epidemic: By the Numbers. Available at https://www.hhs.gov/sites/default/files/Factsheet-opioids-061516.pdf. Last accessed July 5, 2017.

58. Gusovsky D. Americans Consume Vast Majority of the World's Opioids. Available at http://www.cnbc.com/2016/04/27/americans-consume-almost-all-of-the-global-opioid-supply.html. Last accessed July 5, 2017.

59. Kenan K, Mack K, Paulozzi L. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000–2010. Open Med. 2012;6(2):e41.

60. National Center for Health Statistics. Health, United States, 2010. Hyattsville, MD: CDC and NCHS; 2010.

61. Hernandez SH, Nelson LS. Prescription drug abuse: insight into the epidemic. Clin Pharmacol Ther. 2010;88:307-318.

62. U.S. Food and Drug Administration. Drug Utilization Patterns for Hydrocodone ER and Other ER/LA Opioid Analgesics 2011–2015. Available at https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM506638.pdf. Last accessed July 5, 2017.

63. Gill R. Outpatient Drug Utilization Patterns for Selected Opioid Analgesics in the U.S., Years 2007–2011. Available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM333218.pdf. Last accessed July 5, 2017.

64. Lembke A. Why doctors prescribe opioids to known opioid abusers. N Engl J Med. 2012;367:1580-1581.

65. Croft P, Blyth FM, van der Windt D. The global occurrence of chronic pain: an introduction. In: Croft P, Blyth FM, van der Windt D (eds). Chronic Pain Epidemiology: From Aetiology to Public Health. Oxford: Oxford University Press; 2010.

66. Harkness EF, Macfarlane GJ, Silman AJ, McBeth J. Is musculoskeletal pain more common now than 40 years ago? Two population-based cross-sectional studies. Rheumatology (Oxford). 2005;44:890-895.

67. Freburger JK, Holmes GM, Agans RP, et al. The rising prevalence of chronic low back pain. Arch Intern Med. 2009;169:251-258.

68. Substance Abuse and Mental Health Services Administration. Emergency Department Data. Available at https://www.samhsa.gov/data/emergency-department-data-dawn. Last accessed July 5, 2017.

69. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The DAWN Report: Highlights of the 2011 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.

70. SAMHSA, Hughes A, Williams MR, Lipari RN, et al. National Survey on Drug Use and Health. NSDUH Data Review: Prescription Drug Use and Misuse in the United States: Results from the 2015 National Survey on Drug Use and Health. Available at https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR2-2015/NSDUH-FFR2-2015.pdf. Last accessed July 5, 2017.

71. Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014.

72. Shield KD, Jones W, Rehm J, Fischer B. Use and nonmedical use of prescription opioid analgesics in the general population of Canada and correlations with dispensing levels in 2009. Pain Res Manag. 2013;18(2):69-74.

73. McCabe SE, Boyd CJ, Cranford JA, Teter CJ. Motives for nonmedical use of prescription opioids among high school seniors in the United States. Arch Pediatr Adolesc Med. 2009;163(8):739-744.

74. McCabe SE, West BT, Teter CJ, Boyd CJ. Medical and nonmedical use of prescription opioids among high school seniors in the United States. Arch Pediatr Adolesc Med. 2012;166(9):797-802.

75. McCabe SE, West BT, Boyd CJ. Leftover prescription opioids and nonmedical use among high school seniors: a multi-cohort national study. J Adolesc Health. 2013;52(4):480-485.

76. Ballantyne JC, LaForge KS. Opioid dependence and addiction during opioid treatment of chronic pain. Pain. 2007;129(3):235-255.

77. Fishbain DA, Cole B, Lewis J, et al. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9(4):444-459.

78. Boscarino JA, Rukstalis MR, Hoffman SN, et al. Prevalence of prescription opioid-use disorder among chronic pain patients: comparison of the DSM-5 vs. DSM-IV diagnostic criteria. J Addict Dis. 2011;30(3):185-194.

79. Ballantyne JC, Sullivan MD, Kolodny A. Opioid dependence vs. addiction: a distinction without a difference? Arch Intern Med. 2012;172(17):1342-1343.

80. Elander J, Lusher J, Bevan D, Telfer P. Pain management and symptoms of substance dependence among patients with sickle cell disease. Soc Sci Med. 2003;57(9):1683-1696.

81. Manchikanti L, Cash KA, Malla Y, et al. A prospective evaluation of psychotherapeutic and illicit drug use in patients presenting with chronic pain at the time of initial evaluation. Pain Physician. 2013;16(1):E1-E13.

82. Ko JY, Patrick SW, Tong VT, et al. Incidence of neonatal abstinence syndrome – 28 states, 1999-2013. MMWR. 2016;65(31): 799-802.

83. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300(22):2613-2620.

84. Fauber J. Doctors Petition FDA to Change Opioid Labeling. Available at http://www.medpagetoday.com/painmanagement/painmanagement/33900. Last accessed July 5, 2017.

85. Centers for Disease Control and Prevention. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR. 2016;65(50-51):1445-1452.

86. Centers for Disease Control and Prevention. Opioid Overdose. Drug Overdose Death Data. Available at https://www.cdc.gov/drugoverdose/data/statedeaths.html. Last accessed July 5, 2017.

87. Cortez M. Opioids Given to Almost 1 in 4 Medicaid Patients, Study Finds. Available at https://www.bloomberg.com/news/articles/2017-06-21/opioids-given-to-almost-1-in-4-medicaid-patients-study-finds. Last accessed July 5, 2017.

88. Centers for Disease Control and Prevention. Overdose deaths involving prescription opioids among Medicaid enrollees—Washington, 2004–2007. MMWR. 2009;58(42);1171-1175.

89. Seattle Times Staff. Seattle Times Methadone Investigation Wins Pulitzer Prize. Available at http://www.seattletimes.com/seattle-news/seattle-times-methadone-investigation-wins-pulitzer-prize. Last accessed July 5, 2017.

90. Berens MJ, Armstrong K. State Pushes Prescription Painkiller Methadone, Saving Millions but Costing Lives. Available at http://www.seattletimes.com/seattle-news/times-watchdog/state-pushes-prescription-painkiller-methadone-saving-millions-but-costing-lives. Last accessed July 5, 2017.

91. Centers for Disease Control and Prevention. Vital Signs: overdoses of prescription opioid pain relievers and other drugs among women—United States, 1999–2010. MMWR. 2013;62(26);537-542.

92. Coplan P, Wentworth C, Downing J, et al. The risk of opioid overdose among patients receiving higher versus lower doses of extended-release opioids in the UK. J Pain. 2013;14(4 Suppl):S18.

93. Centers for Disease Control and Prevention. Vital Signs: risk for overdose from methadone used for pain relief—United States, 1999–2010. MMWR. 2012;61(26):493-497.

94. Madadi P, Hildebrandt D, Lauwers AE, Koren. Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in Ontario, Canada. PLoS ONE. 2013;8(4):e60600.

95. Boyles S. CDC: Alarming Increase in Methadone Deaths: Deaths from Opioid Painkillers have Tripled since 1999. Available at http://www.webmd.com/pain-management/news/20090930/alarming-increase-in-methadone-deaths. Last accessed July 5, 2017.

96. Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician. 2010;13(5):401-435.

97. Lexicomp Online. Available at http://online.lexi.com. Last accessed July 5, 2017.

98. The Joint Commission. Safe use of opioids in hospitals. Sentinel Event Alert. 2012;49:1-5.

99. The CBHSQ Report. Drug-Related Suicide Attempts by Middle-Aged Adults Likely to Involve Alcohol Combined with Drugs. Available at https://www.samhsa.gov/data/sites/default/files/report_2096/Spotlight-2096.pdf. Last accessed July 5, 2017.

100. Brauser D. ED Visits for Drug-Related Suicide Attempts Double. Available at http://www.medscape.com/viewarticle/829569. Last accessed July 5, 2017.

101. Hitchcock LS, Ferrell BR, McCaffery M. The experience of chronic nonmalignant pain. J Pain Symptom Manage. 1994;9:312-318.

102. Cheatle MD. Depression, chronic pain, and suicide by overdose: on the edge. Pain Med. 2011;12(Suppl 2):S43-S48.

103. Smith MT, Edwards RR, Robinson RC, Dworkin RH. Suicidal ideation, plans, and attempts in chronic pain patients: factors associated with increased risk. Pain. 2004;111(1-2):201-208.

104. Ratcliffe GE, Enns MW, Belik SL, Sareen J. Chronic pain conditions and suicidal ideation and suicide attempts: an epidemiologic perspective. Clin J Pain. 2008;24(3):204-210.

105. Tang NK, Crane C. Suicidality in chronic pain: a review of the prevalence, risk factors and psychological links. Psychol Med. 2006; 36(5):575-586.

106. Torrance N, Elliott AM, Lee AJ, Smith BH. Severe chronic pain is associated with increased 10 year mortality: a cohort record linkage study. Eur J Pain. 2010;14(4):380-386.

107. Drew DJ, St. Marie BJ. Pain in critically ill patients with substance use disorder or long-term opioid use for chronic pain. AACN Adv Crit Care. 2011;22(3):238-254.

108. Apkarian AV, Sosa Y, Sonty S, et al. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density.J Neuroscience. 2004;24(46):10410-10415.

109. Golub A, Elliott L, Brownstein HH. The opiate pain reliever epidemic among U.S. arrestees, 2000–2010: regional and demographic variations. J Ethn Subst Abuse. 2013;12(1):1-29.

110. Fishman SM. Responsible Opioid Prescribing: A Clinician's Guide. 2nd ed. Washington, DC: Waterford Life Sciences; 2012.

111. U.S. Food and Drug Administration. Medication Guides: Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS). Available at https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM244570.pdf. Last accessed July 5, 2017.

112. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.

113. Gourlay DL, Heit HA. Universal precautions revisited: managing the inherited pain patient. Pain Med. 2009;10(Suppl 2):S115-S123.

114. Manchikanti L, Kaye AM, Knezevic NN, et al. Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. Pain Physician. 2017;20(2S):S3-S92.

115. Butler SF, Budman SH, Fernandez KC, et al. Cross-validation of a screener to predict opioid misuse in chronic pain patients (SOAPP-R). J Addict Med. 2009;3(2):66-73.

116. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.

117. Fine PG, Finnegan T, Portenoy RK. Protect your patients, protect your practice: practical risk assessment in the structuring of opioid therapy in chronic pain. J Fam Pract. 2010;59(9 Suppl 2):S1-S169.

118. Katz NP. Opioid Prescribing Toolkit: A Workbook for Clinicians. New York, NY: Oxford University Press; 2010.

119. Webster LR. Eight Principles for Safe Opioid Prescribing. Paper presented at: American Academy of Pain Medicine Annual Meeting; April 2013; Fort Lauderdale, FL.

120. Katz NP, Birnbaum H, Brennan MJ. Prescription opioid abuse: challenges and opportunities for payers. Am J Manag Care. 2013;19(4):295-302.

121. American Chronic Pain Association. ACPA Resource Guide to Chronic Pain Treatment: 2016 Edition. Available at https://www.theacpa.org/uploads/documents/ACPA_Resource_Guide_2016.pdf. Last accessed July 5, 2017.

122. American Pharmacists Association. VIGIL Helps Pharmacists Screen Controlled Substances. Available at http://www.pharmacist.com/vigil-helps-pharmacists-screen-controlled-substances. Last accessed July 5, 2017.

123. Strickland JM, Huskey A, Brushwood DB. Pharmacist-physician collaboration in pain management practice. J Opioid Manag. 2007;3(6):295-301.

124. Crespi-Lofton J. VIGIL: answer the question, "Is it legitimate?" Pharm Today. 2006;12(1):1.

125. Passik SD, Kirsh KL, Whitcomb L, et al. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther. 2004;26(4):552-561.

126. Atluri SL, Akbik H, Sudarshan G. Prevention of opioid abuse in chronic non-cancer pain: an algorithmic, evidence-based approach. Pain Physician. 2012;15(3 Suppl):ES177-ES189.

127. Meier B. Increase in Urine Testing Raises Ethical Questions. Available at http://www.nytimes.com/2013/08/02/business/increase-in-urine-testing-raises-ethical-questions.html. Last accessed July 5, 2017.

128. Sekhon R, Aminjavahery N, Davis CN Jr, et al. Compliance with opioid treatment guidelines for chronic noncancer pain (CNCP) in primary care at a Veterans Affairs Medical Center (VAMC). Pain Med. 2013;14(10):1548-1556.

129. American College of Preventive Medicine. Use, Abuse, Misuse and Disposal of Prescription Pain Medication Clinical Reference: A Resource from the American College of Preventive Medicine. Available at http://www.acpm.org/?UseAbuseRxClinRef. Last accessed July 5, 2017.

130. Office of National Drug Control Policy. Proper Disposal of Prescription Drugs. Available at https://www.ncjrs.gov/ondcppubs/publications/pdf/prescrip_disposal.pdf. Last accessed July 5, 2017.

131. U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting Opioid Analgesics. Available at http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm163647.htm. Last accessed July 5, 2017.

132. U.S. Food and Drug Administration. Transmucosal Immediate-Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS). Available at https://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm289730.pdf. Last accessed July 5, 2017.

133. Webster L, St Marie B, McCarberg B, et al. Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain. J Opioid Manag. 2011;7(3):235-245.

134. Stanos SP, Bruckenthal P, Barkin RL. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. Mayo Clin Proc. 2012;87(7):683-694.

135. Green TC. Cumulative Impacts of ADFs/TRFs: Evidence from ASI-MV and the RARx Study. Paper presented at: 7th Annual RADARS Scientific Meeting; April 2013; Rockville, MD.

136. Budman SH, Grimes Serrano JM, Butler SF. Can abuse-deterrent formulations make a difference? Expectation and speculation. Harm Reduct J. 2009;29:6-8.

137. Passik SD, Hays L, Eisner N, Kirsh KL. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliative Care Pharmacother. 2006;20(2):5-13.

138. U.S. Food and Drug Administration. FDA Issues Draft Guidance on Abuse-Deterrent Opioids. Available at https://wayback.archive-it.org/7993/20161023125734/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm334785.htm. Last accessed July 5, 2017.

139. Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14(4): 351-358.

140. Severtson SG, Bartelson BB, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain. 2013;14(10):1122-1130.

141. Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013;22(12):1274-1282.

142. Cicero TJ, Ellis MS. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin. JAMA Psychiatry. 2015;72(5):424-430.

143. Behm A, Low KM, Medina M. Opioids with abuse-deterrent technologies: what role do they play in managing chronic pain in older adults? Clin Geriatr. 2012;20(7):26-32.

144. U.S. Food and Drug Administration. FDA Approves Abuse-Deterrent Labeling for Reformulated OxyContin: Agency Will Not Approve Generics to Original OxyContin. Available at https://wayback.archive-it.org/7993/20170112223041/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm348252.htm. Last accessed July 5, 2017.

145. Adams S. Painkiller Abuse Spurs Search for a Safer Opioid Therapy. Available at https://www.firstwordpharma.com/node/1115714?tsid=17. Last accessed July 5, 2017.

146. U.S. Food and Drug Administration. FDA Approves Extended-Release, Single-Entity Hydrocodone Product with Abuse-Deterrent Properties. Available at https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm420978.htm. Last accessed July 5, 2017.

147. U.S. Food and Drug Administration. FDA Requests Removal of Opana ER for Risks Related to Abuse. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562401.htm. Last accessed July 5, 2017.

148. Magnani B, Kwong T. Urine drug testing for pain management. Clin Lab Med. 2012;32(3):379-390.

149. Reifler LM, Droz D, Bailey JE, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012;13(3):434-442.

150. Hannon K. The Prescription Drug Crisis in New York State: A Comprehensive Approach. Available at http://www.scribd.com/doc/82474334/Prescription-Drug-Abuse-Crisis-in-NYS-Comprehensive-Approach-New. Last accessed July 5, 2017.

151. Kraman P. Rx for Prescription Drug Abuse. Available at http://www.csg.org/knowledgecenter/docs/sn0405RxPrescriptionAbuse.pdf. Last accessed July 5, 2017.

152. Centers for Disease Control and Prevention. Opioid Overdose: State Prescription Drug Laws. Available at https://www.cdc.gov/drugoverdose/policy/laws.html. Last accessed July 5, 2017.

153. Meier B. FDA Urging a Tighter Rein on Painkillers. Available at http://www.nytimes.com/2013/10/25/business/fda-seeks-tighter-control-on-prescriptions-for-class-of-painkillers.html. Last accessed July 5, 2017.

154. WorkCompWire. NCOIL Takes Lead on Best Practices to Curb Opioid Abuse. Available at NCOIL Proposed Best Practices to Address Opioid Abuse, Misuse or Diversion. Last accessed June 15, 2017.

155. Physicians for Responsible Opioid Prescribing. Regulate Labeling of Opioid Analgesics: Docket FDA-2012-P-0818. Available at https://www.noticeandcomment.com/FDA-2012-P-0818-fdt-416.aspx. Last accessed July 5, 2017.

156. Ashby M, Fleming B, Wood M, et al. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients.J Pain Symptom Manage. 1997;14(3):157-167.

157. Schneider J, Anderson A, Tennant F. Patients who require ultra-high opioid doses. Pract Pain Manag. 2009;9(7):10-16.

158. Holmquist GL. Opioid metabolism and effects of cytochrome P450. Pain Med. 2009;10(Suppl 1):S20-S29.

159. Clarke T. U.S. War on Drugs Moves to Pharmacy from Jungle. Available at http://www.reuters.com/article/2012/06/16/dea-prescription-drugs-idUSL1E8HC9GU20120616. Last accessed July 5, 2017.

160. Ryan H. Heroin Resurgence An 'Unintended Consequence' of Attempt to Curb OxyContin Abuse, Study Finds. Available at http://www.latimes.com/local/lanow/la-me-oxycontin-20170109-story.html. Last accessed July 5, 2017.

161. Alpert A, Powell D, Pacula RL. Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids. Available at http://www.nber.org/papers/w23031. Last accessed July 5, 2017.

162. Lipari RN, Hughes A. Trends in Heroin Use in the United States: 2002 to 2013. Available at https://www.samhsa.gov/data/sites/default/files/report_1943/ShortReport-1943.html. Last accessed July 5, 2017.

163. National Institute on Drug Abuse. What is the Scope of Heroin Use in the United States. Available at https://www.drugabuse.gov/publications/research-reports/heroin/scope-heroin-use-in-united-states. Last accessed July 5, 2017.

164. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367;187-189.

165. Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013;22(12):1274-1282.

166. Ryan H, Glover S, Girion L. How Black-Market OxyContin Spurred a Town's Descent Into Crime, Addiction and Heartbreak. Available at http://www.latimes.com/projects/la-me-oxycontin-everett. Last accessed July 5, 2017.

167. American Society of Addiction Medicine. Effective Rx Thwarted for Deadly Opioid Epidemic. Available at https://www.asam.org/docs/default-source/pressreleases/effective-rx-thwarted-for-deadly-opioid-epidemic. Last accessed July 5, 2017.

168. Ballantyne JC. Opioids for chronic nonterminal pain. South Med J. 2006;99(11):1245-1255.

169. Fleming MF, Balousek SL, Klessig CL, et al. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8(7):573-582.

170. Substance Abuse and Mental Health Services Administration. Managing Chronic Pain in Adults With or in Recovery from Substance Use Disorders. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011.

171. Savage SR. What to do when pain and addiction coexist. Chronic Pain Perspect. 2013;62(6 Suppl):S10-S16.

172. Sanders SH, Harden RN, Vicente PJ. Evidence-based clinical practice guidelines for interdisciplinary rehabilitation of chronic nonmalignant pain syndrome patients. Pain Pract. 2005;5(4):303-315.

173. White WL. Medication-assisted recovery from opioid addiction: historical and contemporary perspectives. J Addict Dis. 2012;31(3):199-206.

174. Aston-Jones G, Harris GC. Brain substrates for increased drug seeking during protracted withdrawal. Neuropharmacology. 2004;47(Suppl 1):167-179.

175. National Institute on Drug Abuse. Topics in Brief: Medication-Assisted Treatment for Opioid Addiction. Available at https://www.drugabuse.gov/sites/default/files/tib_mat_opioid.pdf. Last accessed July 5, 2017.

176. Tetrault JM, Fiellin DA. Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. Drugs. 2012;72(2):217-228.

177. National Institute on Drug Abuse. Principles of Drug Addiction Treatment: A Research-Based Guide (Third Edition). Available at http://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition/principles-effective-treatment. Last accessed July 5, 2017.

178. Treatment Research Institute. FDA approved medications for the treatment of opiate dependence: literature reviews on effectiveness and cost-effectiveness. In: Advancing Access to Addiction Medications: Implications for Opioid Addiction Treatment. Rockville, MD: American Society of Addiction Medicine; 2013: 13-15.

179. Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Rockville, MD: U.S. Department of Health and Human Services; 2005.

180. Colson J, Helm S, Silverman S. Office-based opioid dependence treatment. Pain Physician. 2012;15(3 Suppl):ES231-ES236.

181. Kampman, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. Available at https://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/asam-national-practice-guideline-jam-article.pdf. Last accessed July 5, 2017.

182. Drug Enforcement Administration, Diversion Control Division. DEA Requirements for DATA Waived Physicians (DWPs). Available at https://www.deadiversion.usdoj.gov/pubs/docs/dwp_buprenorphine.htm. Last accessed July 5, 2017.

183. Kahan M, Wilson L, Mailis-Gagnon A, Srivastava A; National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations. Can Fam Physician. 2011;57(11):1269-1276, e419-e428.

184. Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002;1(1):13-20.

185. Van den Brink W, Haasen C. Evidence-based treatment of opioid-dependent patients. Can J Psychiatry. 2006;51(10):635-646.

186. Specka M, Finkbeiner T, Lodemann E, et al. Cognitive-motor performance of methadone-maintained patients. Eur Addict Res. 2000;6(1):8-19.

187. White W. Long-Term Strategies to Reduce the Stigma Attached to Addiction, Treatment, and Recovery within the City of Philadelphia (with Particular Reference to Medication-Assisted Treatment/Recovery). Philadelphia, PA: Department of Behavioral Health and Mental Retardation Services; 2009.

188. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284(13):1689-1695.

189. Olsen Y, Alford DP. Chronic pain management in patients with substance use disorders. Adv Stud Med. 2006;6(3):111-123.

190. Becker WC, Fraenkel L, Kerns RD, Fiellin DA. A research agenda for enhancing appropriate opioid prescribing in primary care. J Gen Intern Med. 2013;28(10:1364-1367.

191. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016;315(15):1624-1645.

192. Macerollo AA, Mack DO, Oza R, Bennett IM, Wallace LS Academic family medicine physicians' confidence and comfort with opioid analgesic prescribing for patients with chronic nonmalignant pain. J Opioid Manag. 2014;10(4):255-261.

193. Pitkin RM, Branagan MA, Burmeister LF. Accuracy of data in abstracts of published research articles. JAMA. 1999;281(12):1110-1111.

194. Bekelman JE, Li Y, Gross CP: Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289(4):454-465.

195. McGauran N, Wieseler B, Kreis J, Schüler YB, Kölsch H, Kaiser T. Reporting bias in medical research: a narrative review. Trials. 2010;11:37.

196. Ross JS, Mulvey GK, Hines EM, et al. Trial publication after registration in ClinicalTrials.gov: a cross-sectional analysis. PLoS Med. 2009;6(9):e1000144.

197. Mathieu S, Boutron I, Moher D, et al. Comparison of registered and published primary outcomes in randomized controlled trials. JAMA. 2009;302(9):977-984.

198. Prayle AP, Hurley MN, Smyth AR. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross-sectional study. BMJ. 2012;344:d7373.

199. Veitch E. Silent Takedown of the Pharma Trials Database…and More. Available at http://blogs.plos.org/speakingofmedicine/2012/03/23/silent-takedown-of-the-pharma-trials-database. Last accessed July 5, 2017.

200. Prasad V, Cifu A, Ioannidis JPA. Reversals of established medical practices: evidence to abandon ship. JAMA. 2012;307(1):37-38.

201. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;8(2)696-701.

202. Chew M. Researchers, like politicians, use "spin" in presenting their results, conference hears. BMJ. 2009;339:b3779.

203. Yavchitz A, Boutron I, Bafeta A, et al. Misrepresentation of randomized controlled trials in press releases and news coverage: a cohort study. PLoS Med. 2012;9:e1001308.

204. Centers for Disease Control and Prevention. Vital Signs: Prescription Painkiller Overdoses in the U.S. Available at http://www.cdc.gov/vitalsigns/painkilleroverdoses. Last accessed July 5, 2017.

205. Paulozzi LJ, Jones CM, Mack KA, Rudd RA. Vital Signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR. 2011;60(43):1487-1492.

206. Shaneyfelt TM, Centor RM. Reassessment of clinical practice guidelines. JAMA. 2009;301(8):868-869.

207. Sniderman AD, Furberg CD. Why guideline-making requires reform. JAMA. 2009;301(4):429-431.

208. Pannucci CJ, Wilkins EG. Identifying and avoiding bias in research. Plast Reconstr Surg. 2010;126(2):619-625.

209. Mills JL. Data torturing. N Engl J Med. 1993;329(16):1196-1199.

210. Greenhalgh T. How to read a paper: statistics for the non-statistician. II: "significant" relations and their pitfalls. BMJ. 1997;315(7105):422-425.

211. Centers for Disease Control and Prevention. Policy Impact: Prescription Painkiller Overdoses. Available at https://www.cdc.gov/drugoverdose/pdf/policyimpact-prescriptionpainkillerod-a.pdf. Last accessed July 5, 2017.

212. Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study. Addiction. 2007;102(2):289-300.

213. Schmittner J, Krantz MJ. QTc prolongation in methadone maintenance: fact and fiction. Heroin Addict Relat Clin Probl. 2006;8(4):41-52.

214. Prochazka J, Hejcl A, Prochazkova L. Intrathecal midazolam as supplementary analgesia for chronic lumbar pain: 15 years' experience. Pain Med. 2011;12(9):1309-1315.

215. Bogduk N. When data are not proof. Pain Med. 2011;12(9):1297-1298.

216. Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. MMWR. 2018;67(12):349-358.

217. U.S. Food and Drug Administration. FDA Approves the First Non-Opioid Treatment for Management of Opioid Withdrawal Symptoms in Adults. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607884.htm. Last accessed May 24, 2018.

Evidence-Based Practice Recommendations Citations

1. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2—guidance. Pain Physician. 2012;15(3 Suppl):S67-S116. Summary retrieved from National Guideline Clearinghouse at https://www.guideline.gov/summaries/summary/38257. Last accessed June 28, 2017.

2. Hooten M, Thorson D, Bianco J, et al. Pain: Assessment, Non-Opioid Treatment Approaches and Opioid Management. Bloomington, MN: Institute for Clinical Systems Improvement; 2016 Summary retrieved from National Guideline Clearinghouse at https://www.guideline.gov/summaries/summary/50568. Last accessed June 28, 2017.


Copyright © 2017 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.